21:41 , Jul 20, 2017 |  BC Innovations  |  Product R&D

Eureka moment for TCR mimics

In the race to access the wealth of intracellular molecular targets once considered undruggable, Eureka Therapeutics Inc. is pioneering TCR-like antibodies that capitalize on the ability of TCRs to recognize tumor antigens. But the company...
19:38 , Nov 11, 2016 |  BC Week In Review  |  Clinical News

Bremelanotide: Ph III data

Top-line data from a total of 1,202 premenopausal women with HSDD in the modified intent-to-treat (mITT) populations of the identical, 24-week, double-blind, U.S. and Canadian Phase III Reconnect Studies 301 and 302 showed that 1.75...
07:00 , May 30, 2016 |  BioCentury  |  Strategy

Taking Takeda global

Two years after joining Takeda Pharmaceutical Co. Ltd., Christophe Weber has narrowed the company's therapeutic focus, expanded the executive team and reorganized its approach to market with the aim of transforming the company into a...
07:00 , Oct 22, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Wilms tumor 1 (WT1); CD3e molecule epsilon (CD3-TCR complex)(CD3ε; CD3E)

Cancer INDICATION: Cancer; leukemia Cell culture and mouse studies suggest a bispecific T cell engager (BiTE) antibody targeting WT1 and CD3ε could help treat cancer and leukemia. The BiTE consisted of ESK1 - which is a T...
08:00 , Jan 19, 2015 |  BC Week In Review  |  Clinical News

Bremelanotide: Phase III started

Palatin began the 32-week, double-blind, placebo-controlled, North American Phase III reconnect study to evaluate subcutaneous bremelanotide self-administered as needed in about 550 premenopausal women with hypoactive sexual desire disorder (HSDD) -- a subtype of FSD....
07:00 , Aug 4, 2014 |  BC Week In Review  |  Clinical News

Tefina: Phase II data

The double-blind, international Phase II AMB-2012-01 trial in 253 pre- and post-menopausal women experiencing acquired female orgasmic disorder showed that 0.6 mg Tefina as needed for 84 days met the primary endpoint of improving the...
08:00 , Feb 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Mucopolysaccharidosis a-l-iduronidase (IDUA) In vitro and mouse studies suggest megakaryocyte-targeted gene therapy could help treat mucopolysaccharidosis...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Company News

Genetic Alliance other news

Genetic Alliance issued a request for proposals to offer its crowd-sourced Platform for Engaging Everyone Responsibly (PEER). Genetic Alliance will offer a customized, organization-branded installation of PEER to up to nine disease and/or condition advocacy...
07:00 , Mar 28, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Leukemia; solid tumors Human leukocyte antigen (HLA); Wilms tumor 1 (WT1) Mouse and cell culture studies suggest...
07:00 , Mar 28, 2013 |  BC Innovations  |  Targets & Mechanisms

mAb attack on WT1

Wilms tumor 1 is overexpressed in many different cancers, but most antibody and small molecule developers have deemed it undruggable because it is an intracellular transcription factor. Now, researchers at Eureka Therapeutics Inc. and the...